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Positive allosteric modulators (PAMs) of nicotinic acetylcholine receptors (nAChRs) have attracted
considerable interest as a novel area of therapeutic drug discovery. Two types of a7-selective PAMs have
been identiﬁed (type I and type II). Whilst both potentiate peak agonist-induced responses, they have
different effects on the rate of agonist-induced receptor desensitization. Type I PAMs have little or no
effect on the rapid rate of desensitization that is characteristic of a7 nAChRs, whereas type II PAMs cause
dramatic slowing of receptor desensitization. Previously, we have obtained evidence indicating that PNU-
120596, a type II PAM, causes potentiation by interacting with an allosteric transmembrane site. In
contrast, other studies have demonstrated the importance of the ‘M2eM3 segment’ in modulating the
effects of the type I PAM NS1738 and have led to the proposal that NS1738 may interact with the
extracellular N-terminal domain. Here, our aim has been to compare the mechanism of allosteric
potentiation of a7 nAChRs by NS1738 and PNU-120596. Functional characterization of a series of
mutated a7 nAChRs indicates that mutation of amino acids within a proposed intrasubunit trans-
membrane cavity have a broadly similar effect on these two PAMs. In addition, we have employed
a functional assay designed to examine the ability of ligands to act competitively at either the orthosteric
or allosteric binding site of a7 nAChRs. These data, together with computer docking simulations, lead us
to conclude that both the type I PAM NS1738 and the type II PAM PNU-120596 bind competitively at
a mutually exclusive intrasubunit transmembrane site.
 2011 Elsevier Ltd. Open access under CC BY license.1. Introduction
Nicotinic acetylcholine receptors (nAChRs) are a diverse family
of pentameric neurotransmitter receptors (Millar and Gotti, 2009)
and are members of the larger super-family of ligand-gated ion
channels (Lester et al., 2004). Although many nAChR subtypes have
been identiﬁed in the mammalian brain, a7 nAChRs are somewhat
unusual in forming functional homomeric receptors (Couturier
et al., 1990). In recent years, the a7 nAChR has attracted consider-
able interest as a target for drug discovery (Haydar and Dunlop,
2010) due, in part, to evidence that it may have a cognitive
enhancing role. Nicotinic receptors are complex allosteric proteins
with the possibility of a variety of modulatory ligand binding sites
(Taly et al., 2009). In addition to a7-selective agonists and; fax: þ44(0)20-7679-7243.
iversity of Cambridge, Tennis
Y license.antagonists, a number of a7-selective positive allosteric modulators
(PAMs) have been reported in recent years (for recent reviews, see
Faghih et al., 2008; Malysz et al., 2009). Recent studies have also
provided evidence that a7-selective PAMs may have cognitive
enhancing effects and, as a consequence, may be of use in the
treatment of neurological and psychiatric disorders such as Alz-
heimer’s disease and schizophrenia (Timmermann et al., 2007).
Positive allosteric modulators have been classiﬁed as either ‘type I’
or ‘type II’ potentiators, on the basis of a difference in their effect on
desensitization (Bertrand and Gopalakrishnan, 2007). Whilst both
types of PAM enhance agonist-evoked responses, type II PAMs
cause a dramatic reduction in receptor desensitization (Grønlien
et al., 2007; Hurst et al., 2005).
Two a7-selective PAMs that have been studied in some detail
are NS1738, a type I PAM (Timmermann et al., 2007) and PNU-
120596, a type II PAM (Hurst et al., 2005). Recent evidence has
suggested that the allosteric binding site for PNU-120596 is located
in an intrasubunit cavity located between the four transmembrane
(TM) helices (TM1eTM4; also referred to as M1eM4) of the a7
subunit (Young et al., 2008). This site is similar to the allosteric site
Fig. 1. Chemical structure of a7-selective potentiators NS1738 and PNU-120596. Both
NS1738 (a type I PAM) and PNU-120596 (a type II PAM) are urea compounds con-
taining a halogenated aromatic group.
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neurosteroids acting on GABA- and glycine-gated ion channels
(Hosie et al., 2006; Mihic et al., 1997; Ye et al., 1998). Further
evidence for modulatory binding sites for anaesthetics being
located in the transmembrane region has come from photoafﬁnity
labelling studies conducted with puriﬁed Torpedo nAChRs (Garcia
et al., 2007; Ziebell et al., 2004). In addition, there is evidence to
indicate that the type I PAM ivermectin, a largemacrocyclic lactone,
interacts with a transmembrane site on nAChRs (Collins and Millar,
2010; Sattelle et al., 2009).
Due to the profound differences in their effects on receptor
desensitization, it is possible that a7-selective type I and type II
PAMs may interact at distinct allosteric sites. Indeed, recent studies
with NS1738 demonstrate that a 10 amino acid region described as
being the ‘M2eM3 segment’ has a selective effect onmodulation by
the type I PAM NS1738 and have led to the suggestion that NS1738
may interact with the N-terminal extracellular domain of a7
nAChRs (Bertrand et al., 2008). Here, we have examined the allo-
stericmodulation of a7 nAChRs by a type I PAM (NS1738) and a type
II PAM (PNU-120596). We have examined the effects on allosteric
modulation of a series of site-directed mutations and have per-
formed computer docking simulations with an a7 nAChR homology
model. In addition, we have employed an assay designed to
examine whether type I and type II PAMs bind competitively. Based
on these studies, our conclusion is that NS1738 and PNU-120596
bind competitively at a shared allosteric transmembrane site.
2. Materials and methods
2.1. Materials
NS1738 (Timmermann et al., 2007) was generously provided by Daniel Tim-
mermann (NeuroSearch, Denmark). Methyllycaconitine (MLA) and PNU-120596
(Hurst et al., 2005) were obtained from Tocris Bioscience (Bristol, UK). All other
chemicals were obtained from Sigma (Poole, UK).
2.2. Subunit cDNAs and plasmid expression vectors
All experiments were performed with human a7 nAChRs with the exception of
experiments that directly compared mutated and wild type receptors, which were
performed with rat a7 nAChRs. Human nAChR a7 subunit cDNA in plasmid pSP64GL
and rat nAChR a7 subunit cDNA in pcDAN1neo have been described previously
(Broadbent et al., 2006; Séguéla et al., 1993). Mutated rat a7 cDNAs have been
described previously and were used (rather than mutated human cDNAs) to enable
a direct comparison with data reported previously with PNU-120596 (Young
et al., 2008).
2.3. Xenopus oocyte electrophysiology
Xenopus laevis oocytes were isolated and defolliculated as described previously
(Young et al., 2007). To express rat a7 nAChR (for experiments comparing mutant
and wild type receptors), oocyte nuclei were injected with cDNAs cloned down-
stream from a CMV promoter in plasmid expression vectors (Young et al., 2007). To
express human a7 nAChRs (for experiments other than those examining point
mutations) in vitro transcribed cRNAwas injected into the oocyte cytoplasm. In vitro
transcription of cRNA was carried out using mMESSAGE mMACHINE T7 transcrip-
tion kit (Ambion, Huntington, UK). Oocytes were injected with 2e20 ng DNA or 2 ng
cRNA per oocyte in a volume of 18.4 nl using a Drummond variable volume
microinjector. Experiments were performed, typically, 2e4 days after injection of
oocytes with cDNA or cRNA. Two-electrode voltage-clamp recordings were per-
formed (with the oocyte membrane potential held at 60 mV), as described
previously (Young et al., 2007) using either an Axon Geneclamp 500B ampliﬁer,
Axon DigiData 1200 and pClamp software (Molecular Devices, Sunnyvale, CA) or
with aWarner Instruments OC-725C ampliﬁer (Harvard Apparatus, Edenbridge, UK),
PowerLab 8SP and Chart 5 software (AD Instruments, Oxford, UK). Agonists and
PAMs were applied to oocytes using a BPS-8 solenoid valve solution exchange
system (ALA Scientiﬁc Inc., Westbury, NY), controlled by either pClamp or Chart
software. For most experiments, acetylcholine was used at either a maximal or EC20
concentration (1 mM and 50 mM, respectively) and PAMs were used at maximal
concentrations (10 mM for NS1738 and 3 mM for PNU-120596). Except were stated
otherwise, PAMs were pre-applied for 20 s and were then co-applied with
acetylcholine.2.4. Computer docking simulations
Computational molecular docking of NS1738 were performed with AUTODOCK 4
(Morris et al., 1998) using a homology model of the human a7 nAChR trans-
membrane region, as described previously (Cheng et al., 2007; Young et al., 2008). To
avoid bias, initial studies employed a ‘blind docking’ approach (Hetényi and van der
Spoel, 2006) in which no assumptions were made concerning where within the
transmembrane region ligands might be expected to bind. Flexibility of rotatable
bonds in docked ligands was permitted during the docking simulation but with
a rigid homology model. Subsequently, docking simulations were performed in
which ﬂexibility was allowed for the side chains of ﬁve amino acid [S222 (TM1),
A225 (TM1), M253 (TM2), F455 (TM4) and C459 (TM4)] that have been implicated
by site-directed mutagenesis as inﬂuencing potency of allosteric modulators. Pre-
dicted Gibbs free energy of binding (DG) was calculated as described (Huey et al.,
2007; Morris et al., 1998), as was the predicted equilibrium constant for binding
(Keq), using the equation Keq ¼ eeDG/RT (where R ¼ gas constant, T ¼ absolute
temperature).
3. Results
3.1. Characterization of mutated a7 nAChRs
The ability of NS1738, a type I PAM, and PNU-120596, a type II
PAM, (Fig. 1) to act as allosteric modulators of a7 nAChRs was
examined by two-electrode voltage-clamp recording in Xenopus
oocytes. Neither compound had signiﬁcant agonist activity on a7
nAChRs at the concentrations tested (Fig. 2A and B) but, when co-
applied with acetylcholine, both caused substantial potentiation
of acetylcholine-evoked responses (Fig. 2A and B). The represen-
tative traces shown in Fig. 2 illustrate an important difference
between type I and type II PAMs. NS1738 has little or no effect on
the rapid desensitization of a7 nAChRs, whereas PNU-120596
causes a dramatic slowing of receptor desensitization.
We have previously reported studies indicating that PNU-
120596 interacts with an intrasubunit cavity in a7 nAChRs
(Young et al., 2008), whereas other recent studies have provided
evidence that potentiation by NS1738 is inﬂuenced by the a7
‘M2eM3 segment’ and, leading to the suggestion that it may
Fig. 2. Positive allosteric modulation of a7 nAChRs by NS1738 and PNU-120596.
Representative traces are shown illustrating agonist-evoked responses with a7
nAChRs expressed in Xenopus oocytes. Application of acetylcholine (1 mM) resulted in
rapidly desensitizing responses that are typical of a7 nAChRs (left hand traces). Pre-
application (20 s) followed by co-application of either NS1738 (10 mM) or PNU-
120596 (3 mM) resulted in potentiation of responses evoked by acetylcholine (right
panels). In contrast, no agonist activity was observed when NS1738 (10 mM) and PNU-
120596 (3 mM) were applied in the absence of acetylcholine (middle traces). Appli-
cations of acetylcholine and PAMs are indicated by horizontal lines.
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2008). With the aim of exploring in greater detail the interaction
of these allosteric modulators with the a7 nAChR, the inﬂuence of
11 point mutations was examined (Table 1). All of these mutations
are predicted to lie within a cavity located between the four
a helices of the a7 subunit and their effects on potentiation by PNU-
120596 have been reported previously (Young et al., 2008).
On wild type a7 nAChRs, NS1738 potentiated responses to an
EC20 concentration of acetylcholine (50 mM) by 39.5  2.7 fold withTable 1
Inﬂuence of a7 point mutations upon potentiation by NS1738 and PNU-120596.
Subunit/
Mutation
Location Fold potentiation
by NS1738
Fold potentiation
by PNU-120596
Wild type 39.5  2.7 36.7  4.1
G211V TM1 45.9  4.3 35.0  2.2
S222M TM1 6.3  0.5*** 25.7  1.4*
A225D TM1 9.1  0.7*** 3.2  0.3***
L230Y TM1 32.2  2.2 40.1  5.3
M253L TM2 1.9  0.1*** 4.1  0.8***
M260L TM2 4.0  0.3*** 28.5  2.0
Q272V TM3 28.3  5.3 38.4  0.2
S276V TM3 40.7  2.2 40.3  2.7
F455A TM4 11.1  1.1*** 24.7  3.8*
T456V TM4 41.1  1.3 38.3  1.7
C459Y TM4 14.3  3.3*** 15.4  1.3***
Potentiation by a maximal concentration (10 mM) of NS1738 reﬂects the increase in
agonist response with an EC20 concentration of acetylcholine and are compared to
data obtained with a maximal concentration (3 mM) of PNU-120596 (Young et al.,
2008). As reported previously (Young et al., 2008), in most cases mutations had
a minimal effect on acetylcholine potency (the EC20 concentrations of acetylcholine
used in these experiments were 20 mM for M260L, 60 mM for Q272V and 50 mM for
all other mutations and for wild type a7 nAChRs). Data are means of 3e10 inde-
pendent experiments, SEM. Statistical signiﬁcance, determined by ANOVA and
Tukey’s test (NS1738 data F(11,65)¼ 64.6; PNU-120596 data F(11,42)¼ 25.7), *P< 0.05;
***P < 0.001.an EC50 value of 6.7  1.8 mM. Similarly, previous studies from our
laboratory (Young et al., 2008) found that, on wild type a7 nAChRs,
PNU-120596 potentiated responses to an EC20 concentration of
acetylcholine by 36.7  4.1 fold with an EC50 value of 1.5  0.2 mM.
The ability of NS1738 to potentiate agonist-evoked responses was
also examined on 11 mutated a7 nAChRs. In order to facilitate
a comparison of the relative effects of the mutations on NS1738
with those determined previously for PNU-120596, the level of
potentiation has been expressed as a percentage of that observed
with wild type a7 receptors (Fig. 3). Absolute levels of potentiation
observed with NS1738 on mutant a7 nAChRs are presented inFig. 3. Inﬂuence of a7 nAChR transmembrane point mutations upon potentiation by
NS1738 and PNU-120596. Histograms illustrating the inﬂuence of a7 point mutations
on the level of potentiation caused by maximal concentrations of NS1738 (10 mM; open
bars) and PNU-120596 (3 mM; ﬁlled bars). Potentiation of agonist-evoked responses
were determined with an EC20 concentration of acetylcholine (see Table 1). Data are
means  SEM of 3e10 independent experiments (***P < 0.001; Student’s t-test). Data
for PNU-120596 are taken from (Young et al., 2008).
Fig. 5. PNU-120596 (a type II PAM) facilitates recovery of a7 nAChRs from desensiti-
zation. Exposure of a7 nAChR to a high concentration of acetylcholine (1 mM) resulted
in rapid desensitization. The subsequent co-application of NS1738 (10 mM) to desen-
sitized a7 nAChRs had little effect (left hand trace). In contrast, the co-application of
PNU-120596 after desensitization by acetylcholine (3 mM) causes rapid opening,
indicating a recovery from the receptor’s desensitized state (right hand trace).
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tiation by NS1738 and PNU-120596 was broadly similar, suggesting
that these PAMs may interact via a similar site on a7 nAChRs.
However, some differences are apparent (Fig. 3). Two mutations
(S222M and A225D), both of which are located in TM1, signiﬁcantly
reduced levels of potentiation by NS1738 and PNU-120596 but did
so to different extents. S222M had a signiﬁcantly greater effect
(P < 0.001) on NS1738, whereas A225D had a signiﬁcantly greater
effect (P < 0.001) on PNU-120596 (Fig. 3). One mutation M260L,
located in TM2 did not have a signiﬁcant effect on PNU-120596 but
caused a dramatic reduction in potentiation by NS1738 (Fig. 3).
A notable feature of a7 nAChRs containing the M260L mutation is
an alteration in the desensitization proﬁle caused by prolonged
agonist exposure (Fig. 4B). Whereas high concentrations of
acetylcholine causes rapid and complete receptor desensitization in
wild type a7 nAChRs, an initial rapid phase of desensitization was
observed which was followed by a period of sustained receptor
activation in the M260L mutant (Fig. 4B). The extent of receptor
desensitization was determined in response to application of an
EC20 concentration of acetylcholine. The time for responses to
decay to half of the peak response level during continued agonist
application was signiﬁcantly slower for M260L a7 nAChRs
(302  45 ms, n ¼ 10) than for wild type (87  10 ms, n ¼ 9;
P ¼ 0.001). The total charge transfer (area under the curve) during
a 5 s application of acetylcholine (EC20) was also calculated and was
signiﬁcantly greater (2.0  0.1 fold, n ¼ 10, P < 0.001) for M260L
than for wild type a7 nAChRs.3.2. Type II PAM-induced recovery from desensitization
As is illustrated in Fig. 2, NS1738 and PNU-120596 differ mark-
edly in their effects on receptor desensitization. A further striking
difference between type I and type II PAMs is their ability to facil-
itate recovery of a7 nAChRs from desensitization (Young et al.,
2008). After desensitization of a7 nAChRs by prolonged exposure
to a high concentration of acetylcholine, the subsequent co-
application of NS1738 has little effect (Fig. 5A), a ﬁnding that is inFig. 4. Altered receptor desensitization in a7 nAChRs containing the M260L mutation.
A) Model of the TM2 and TM3 transmembrane region derived from the a7 nAChR
homology model (Cheng et al., 2007). The location of a 10 amino acid region ‘M2-M3
segment’ (AEIMPATSDS) described by Bertrand et al. (2008) is shaded in black. Also
illustrated (as black spheres) is the side chain of M260, the amino acid that when
mutated has a selective effect on NS1738. B) Differences in desensitization of wild type
a7 and a7M260L nAChRs are illustrated by responses to 5 s applications of an EC20
concentration of acetylcholine. Solid lines represent normalized means of 9 (wild type
a7) or 10 (a7M260L) independent recordings. Dotted lines represent SEMs.agreement with previous studies conducted with another type I
PAM (Young et al., 2008). In contrast, application of PNU-120596 to
desensitized a7 nAChRs causes rapid reactivation, even in the
continued presence of a desensitizing concentration of acetylcho-
line (Fig. 5B). Thus, persistent (non-desensitized) opening of a7
nAChRs requires the binding of an agonist to the orthosteric site
and a type II PAM to its allosteric site. We would, therefore, expect
recovery from desensitization to be prevented by the displacement
of either acetylcholine or PNU-120596 from their respective
binding sites.We have exploited this fact to examinewhether type I
and type II PAMs bind competitively.3.3. Block of type II PAM-induced recovery from desensitization
a7 nAChRs receptors were activated with a desensitizing
concentration of acetylcholine (1 mM). After desensitization, recep-
tors were then reactivated by the co-application of PNU-120596
(1 mM) in the continued presence of acetylcholine (Fig. 6). After
recovery from desensitization had occurred, a range of concentrations
of NS1738 were then applied in the continued presence of both
acetylcholine and PNU-120596 (Fig. 6). NS1738 caused a dose-
dependent inhibition of the recovery from desensitization
(IC50¼ 5.2 0.4 mM, n¼ 3) (Fig. 6), a ﬁnding that can be explained by
NS1738 causing displacement of PNU-120596 from its binding
site. Similarly, a dose-depended inhibition was observed with the
‘orthosteric’ competitive antagonist MLA (IC50 ¼ 0.8  0.1 mM, n ¼ 3;
Fig. 6).Whereas the inhibition dose-response curve forMLA had a Hill
coefﬁcient close to unity (nH ¼ 1.1  0.1, n ¼ 3), the inhibition curve
for NS1738 had a signiﬁcantly steeper slope (nH¼2.4 0.4, n¼ 3). A
plausible explanation for this difference is thatMLA andNS1738 block
recovery from desensitization by different mechanisms of action
(displacement of acetylcholine from its orthosteric binding site by
MLA and displacement of PNU-120596 from its allosteric binding site
by NS1738). With the aim of testing this hypothesis, the ability of
NS1738 to block recovery from desensitization was re-examined, but
with a higher concentration of either PNU-120596 or acetylcholine. If
NS1738 binds competitively at the PNU-120596 binding site, we
would predict that higher concentrations of NS1738 to be required
when the concentration of PNU-120596 was raised (a rightward shift
Fig. 6. Block of recovery from desensitization by NS1738 and MLA. The ability of PNU-
120596 to cause recovery from desensitization of a7 nAChRs is blocked by NS1738 and
MLA. A) Representative trace showing activation of a7 nAChRs followed by rapid
desensitization in response to acetylcholine (1 mM; lower horizontal line). Subsequent
application of PNU-120596 (1 mM; middle horizontal line) allows recovery from
desensitization. Recovery can be blocked by subsequent application of NS1738 (upper
horizontal line). B) Dose-response curves showing the ability of NS1738 (ﬁlled circles)
and MLA (ﬁlled squares) to block recovery from desensitization caused by co-
application of acetylcholine (1 mM) and PNU-120596 (1 mM). Also shown (open
circles) is the dose-response curve for NS1738 obtained when the experiment was
performed in the presence of the same concentration of acetylcholine but with
a higher concentration of PNU-120596 (3 mM). Data are means  SEM of 3e7 inde-
pendent experiments.
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concentration of acetylcholine would not be expected to have an
effect on inhibition by NS1738. When the experiment was repeated
with a 3-fold higher concentration of PNU-120596 (3 mM, rather than
1 mM) but with the same concentration of acetylcholine (1 mM),
a signiﬁcant (P < 0.05, n ¼ 3) 1.7-fold rightward shift in the NS1738
dose-response curve was observed (IC50 ¼ 8.7  0.9 mM, n ¼ 4). In
contrast, no signiﬁcant shift was observed in the NS1738 dose-
response curve when the experiment was repeated with a 10-fold
higher concentration of acetylcholine (10 mM, rather than 1 mM)
but with the same concentration of PNU-120596 (1 mM).3.4. Computer docking simulations
Computer docking simulations were performed with NS1738
using approaches that we have described previously for PNU-
120596 (Young et al., 2008). Docking simulations employed
a homology model of the transmembrane region of the human a7
nAChR (Cheng et al., 2006). As previously (Young et al., 2008),
a ‘blind docking’ approach was used in which no assumptions were
made about where within the transmembrane homology model
NS1738 might bind. The most favourable (lowest energy) docked
conformation of NS1738 was in a similar location to that identiﬁed
previously for PNU-120596 (Fig. 7), providing support for the
conclusion that NS1738 and PNU-120596 bind at a common or
overlapping site. In addition, the predicted binding free energy (DG)for NS1738 (7.95 kcal/mol; equivalent to a predicted binding
afﬁnity of 1.5 mM) to the homology model was similar to that
reported previously for PNU-120596 (7.98 kcal/mol; 1.41 mM)
(Young et al., 2008). As found previously for PNU-120596, the lowest
energy docked conformation of NS1738 was in very close proximity
(within 6 Å) of the ﬁve amino acids that, when mutated, exert
a signiﬁcant effect on potentiation by NS1738 and PNU-120596
(S222, A225, M253, F455 and C459). Initially, blind docking simu-
lations were performed by allowing ﬂexibility of rotatable bonds
within the ligand but with a rigid homology model. Subsequently,
additional docking simulations were performed in which ﬂexibility
was allowed in the side chains of the ﬁve amino acids that had been
identiﬁed as inﬂuencing potentiation by NS1738 and PNU-120596
(S222, A225, M253, F455 and C459) and by restricting the simula-
tion to the central portion of the homology model. For both ligands,
lower energy (higher predicted afﬁnity) docked conformationswere
identiﬁed when ﬂexibility of these ﬁve side chains was allowed
(Fig. 7). The most favourable conformation of NS1738 identiﬁed
using these docking conditions (DG ¼ 12.07 kcal/mol;
Kd ¼ 1.42 nM) was of similar predicted binding energy to that
reported previously for PNU-120596 in the semi-ﬂexible homology
model (DG ¼ 11.65 kcal/mol; Kd ¼ 2.87 nM).
4. Discussion
In a previous study that examined the modulation of a7 nAChRs
by the type II positive allosteric modulator PNU-120596, it has been
concluded that PNU-120596 acts via an allosteric intrasubunit
transmembrane site (Young et al., 2008). Interestingly, a separate
study has examined the ability of NS1738 to act as a positive allo-
steric modulator of a7 nAChRs and has demonstrated that poten-
tiation by NS1738 is inﬂuenced selectively by a 10 amino acid
‘M2-M3 segment’ (Bertrand et al., 2008). This ﬁnding has, in turn,
led to the suggestion that NS1738 may interact with the extracel-
lular N-terminal domain (Bertrand et al., 2008). In particular, it was
found that the extracellular segment between the second and third
transmembrane domains (the M2eM3 segment) was important in
modulating the allosteric effects of NS1738 but not of the type II
PAM PNU-120596 (Bertrand et al., 2008). A reasonable interpreta-
tion of these previous studies might be that type I PAMs such as
NS1738 and the type II PAM PNU-120596 interact with a7 nAChR at
distinct binding sites. The experiments presented in this paper
were, to a large extent, aimed at examining this possibility. The
main conclusion that we have drawn from the experiments
described herein is that NS1738 and PNU-120596 interact
competitively at a common (mutually exclusive) transmembrane
site. This conclusion is supported by studies of mutated a7 nAChRs
(Fig. 3), experiments involving the co-application of NS1738 and
PNU-120596 (Fig. 6) and by computer docking simulations (Fig. 7).
There is increasing evidence indicating that the a7 trans-
membrane region is the site of action for a range of allosteric
modulators. In addition to evidence that this is the site of action of
NS1738 and PNU-120596, it has been reported that ivermectin,
a large macrocyclic lactone, also interacts with this region of the a7
nAChR (Collins and Millar, 2010; Sattelle et al., 2009). More
recently, it has also been demonstrated that activation of a7
nAChRs by allosteric agonists can occur via this intrasubunit
transmembrane site (Gill et al., 2011). There is, however, also strong
evidence that allosteric modulators can interact with sites on the
nAChR extracellular N-terminal domain. Galantamine, for example,
acts as a nAChR potentiator (albeit much more weakly than PAMs
such as NS1738 and PNU-120596) and has been demonstrated to
bind at an extracellular site (Hansen and Taylor, 2007; Ludwig et al.,
2010). In addition, there is evidence that morantel acts as an allo-
steric modulator of a3b2 nAChRs by binding to the extracellular
Fig. 7. Computer docking simulation with a homology model of the a7 transmembrane domain. Computer docking simulations were performed with AUTODOCK 4 using a homology
model of the a7 nAChR transmembrane domain (Cheng et al., 2007; Young et al., 2008). The backbone of the four transmembrane a helices (TM1-TM4) is shown in grey and the side
chains of amino acids which, when mutated, had a signiﬁcant effect on potentiation by both NS1738 and PNU-120596 (S222, A225, M253, F455 and C459) are shaded in red. The
side chain of M260 (an amino acid that, when mutated, reduced receptor desensitization and had a selective effect on potentiation by NS1738) is shown in blue. The backbone
region corresponding to the 10 amino acid ‘M2-M3 segment’, that has been described previously as having a selective effect on potentiation by NS1738 (Bertrand et al., 2008), is also
shown in blue. The lowest energy (highest predicted binding afﬁnity) docked positions of NS1738 and PNU-120596 are shown in yellow and green, respectively. Initially, a ‘blind
docking’ approach was used in which no assumptions were made as to where within the transmembrane region the compounds might bind (left panel). Subsequently, more
energetically favourable docked conformations were identiﬁed by conducting further simulations focussed upon the central region of the model (where the of the lowest energy
docked conformations are located) using a modiﬁed homology model in which ﬂexibility was permitted within the side chains of the ﬁve amino acid that have been identiﬁed as
inﬂuencing potentiation of NS1738 and PNU-120596 (right panel). For clarity, the lower part of the TM3 a-helical domain has been omitted from the ﬁgure.
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morantel interacts with residues analogous to that of acetylcholine
but at ‘noncanonical’ b-a subunit interface, rather than the
conventional orthosteric a-b interface (Seo et al., 2009). Other
recent studies have revealed the importance of non-acetylcholine-
binding subunit interfaces in a4b2 nAChRs for modulation by Zn2þ
(Moroni et al., 2008). The apparent diversity of modulatory sites on
nAChRs is analogous to the situation in inhibitory Cys-loop recep-
tors such as GABA- and glycine-gated ion channels, where modu-
latory sites have been identiﬁed at both the extracellular domain
(Duncalfe and Dunn, 1996; Pritchett and Seeburg, 1991) and at
transmembrane locations (Hosie and Wilkins, 2006; Mihic et al.,
1997; Ye et al., 1998).
Despite the evidence presented here that NS1738 and PNU-
120596 bind at a common transmembrane site, it is clear that
there are some differences in the mechanism by which these two
compounds interact with a7 nAChRs. Three of the amino acid
mutations examined in the present study (S222M, A225D and
M260L) differed signiﬁcantly in the extent to which they altered
levels of potentiation byNS1738 and PNU-120596 (Fig. 3). However,
such ﬁndings are not unexpected, even if NS1738 and PNU-120596
interact competitively at a common or overlapping site. Such effects
can be accounted for by differences in the chemical structure of
ligands that interact with a common site. Indeed, we might have
expected to ﬁnd such differences in the effects of some mutations,
given the dramatic difference in the extent to which these two
compounds inﬂuence receptor desensitization.
Of the six mutations that were found to substantially reduce the
potency of NS1738 as an allosteric modulator (S222M, A225D,M253L, M260L, F455A and C459Y), ﬁve (all except M260L) have
signiﬁcant and broadly similar effects on potentiation by NS1738
and PNU-120596. Interestingly, all of these ﬁve amino acids lie
towards the bottom of the predicted intrasubunit transmembrane
cavity (Young et al., 2008). The only mutation that we have iden-
tiﬁed that has a selective effect on NS1738 (M260L) is located
towards the top of the TM2 helix (Figs. 4A and 7). Perhaps it is
signiﬁcant that this mutation also results in changes in receptor
desensitization (Fig. 4B). Interestingly, M260L is located within the
10 amino acid region that was identiﬁed previously as being
important in modulating the effects of NS1738 (Bertrand et al.,
2008) and which was described in that study as the ‘short
M2eM3 extracellular domain’. More recently, the same 10 amino
acid region (described as being the ‘M2-M3 loop’) was found to be
critical for potentiation by another type I PAM, genistein (Grønlien
et al., 2010). However, although the 10 amino acid region identiﬁed
in these two previous studies (amino acids AEIMPATSDS) lies
beyond the region that is sometimes referred to as the TM2 (or M2)
domain (Miller, 1989), examination of the high resolution (4 Å)
structure of the Torpedo nAChR (Unwin, 2005) reveals that this 10
amino acid region lies entirely within the TM2 a-helical region,
albeit extending partly above the lipid bilayer. As is illustrated in
the a7 homology model (which was derived from the Torpedo
nAChR structure), M260 lies within the extended a-helical region,
close to the top of the transmembrane region (Figs. 4A and 7).
Interestingly, early models of the helical transmembrane region of
the Torpedo nAChR, generated prior to its detailed three-
dimensional structural determination and based on known
biophysical properties of a helices, suggested that most of this 10
T. Collins et al. / Neuropharmacology 61 (2011) 1306e13131312amino acid region corresponded to an a-helical structure located
within the polar head region of the lipid bilayer (Popot and
Changeux, 1984). However, it has recently been pointed out that
there are differences between the TM2 region of the Torpedo nAChR
structure and the TM2 region from the higher resolution structures
such as the invertebrate glutamate-gated chloride channel (GluCl)
and bacterial ion channels (Corringer et al., 2010; Hibbs and
Gouaux, 2011). A homology model of the a7 nAChR derived from
GluCl would place only the ﬁrst half of the 10 amino acid region
within the TM2 a-helical region of and would locate M260 at the
start of the region linking TM2 and TM3.
Computer docking simulations (Fig. 7) support the idea that
both NS1738 and PNU-120596 bind at a site close to the ﬁve amino
acids that have been identiﬁed as exerting a signiﬁcant effect on
allosteric modulation by both PAMs. In contrast, M260 is located
further away (approximately 9 Å). It is possible that the selective
effect of M260 is primarily a consequence of its effects on receptor
biophysical properties such as desensitization, rather than a more
direct effect at the PAM binding site.
The difference in Hill slopes of inhibition curves for MLA and
NS1738 observed in our co-application experiments (Fig. 6) are
consistent with the possibility that the effects of these compounds
in blocking recovery from desensitization may be due to a different
mechanism of action. Whereas MLA would be expected to cause
displacement of acetylcholine from its extracellular orthosteric
binding site, it is plausible that NS1738 acts by causing displace-
ment of PNU-120596 from its allosteric transmembrane site. This
conclusion is supported by our ﬁnding that changing the concen-
tration of PNU-120596 has a signiﬁcant effect on the inhibition
curve for NS1738, whereas changing the concentration of acetyl-
choline does not (Fig. 6B). This is the result that would be expected
if NS1738 binds competitively with PNU-120596 but binds inde-
pendently of acetylcholine. It could be argued that NS1738 is acting
as a non-competitive antagonist with respect to PNU-120596, by
binding to a third site on the receptor (i.e. distinct from both the
orthosteric acetylcholine binding site and the allosteric PNU-
120596 binding site). This seems unlikely for several reasons. It
would require NS1738 to be exerting a powerful non-competitive
antagonist effect that can surmount the potentiating effect of
PNU-120596. There is no evidence that NS1738 has any direct
antagonist action, indeed it acts as a potent potentiator when co-
applied with acetylcholine. The chemical similarity of NS1738 and
PNU-120596 (Fig. 1), both of which are aromatic-linked urea
compounds, would seem to make the likelihood of a common
binding site plausible and is supported by computer docking
simulations (Fig. 7). Taken together, the data presented in this study
support the conclusion that binding of NS1738 and PNU-120596 to
a7 nAChR is mutually exclusive, just as the binding of agonists and
competitive agonists (such as acetylcholine and MLA) is at the
orthosteric ligand binding site.
5. Conclusion
The simplest explanation for these ﬁndings is that acetylcholine
and MLA bind competitively at the orthosteric binding site (as is
well established) and that NS1738 and PNU-120596 bind compet-
itively at a common or overlapping allosteric binding site. This
explanation for the actions of NS1738 and PNU-120596 is sup-
ported by studies examining the effect of point mutations located at
the postulated transmembrane binding site. This conclusion is also
supported by computer docking simulations that predict that the
most favourable (lowest energy) binding site for NS1738 and PNU-
120596 is at a common transmembrane site, located in very close
proximity to mutations known to affect the ability of NS1738 and
PNU-120596 to act as positive allosteric modulators.Acknowledgements
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